


Lymphoma Epidemiology of Outcomes

Spot Map of LEO Participants' Location as of 2024

- Cornell University
- MD Anderson
- University of Rochester
- Emory
- University of Iowa
- Washington University
- Mayo Clinic
- University of Miami



A Spot Map is a tool researchers use to display information about the study participants. This spot map uses dots to show where each study participant lived at the time they signed up for the study, along with the medical center where they agreed to participate.

Who we are

The LEO study is a collaboration between 8 prominent medical centers and universities around the United States. The goal is to build a large and diverse observational cohort to support a broad research agenda aimed at identifying several factors that impact lymphoma/CLL survivorship.

What we do

We collect data and samples that will help us understand the causes for different types of lymphomas, how we can better treat them, and the best ways to help survivors. Your continued participation in this study is the key to our success!

How to learn more



Visit our website at:
www.leocohort.org
Email us:
leocohort@mayo.edu

See page 2 for results from one of our recent publications and Q&A

Featured Publication

The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes

Published in the American Journal of Hematology in
March of 2024, 99(3):408-421

Summary & Results

This groundbreaking paper presents general information about the demographics, clinical statuses, disease subtypes, and follow-up measures for subjects consented during the first five years of the LEO study (2015-2020). We are hoping that after reading this descriptive paper, researchers will have a better understanding about what data and materials we have collected for the study, so far. This research paper, and the cohort at large, will lead to increased collaborations and research publications as we are well set up to help answer some of the tough questions that still remain about lymphoma.

We want to graciously THANK YOU for your continued support and participation in our research. We can't do it without you!!

LEO Accrual by age as of May 2024

Age	Accrual	Percentage
18-30	332	3.65%
31-40	582	6.40%
41-50	1069	11.76%
51-60	2073	22.81%
61-70	2653	29.19%
71-80	1843	20.28%
81+	537	5.91%
Total Enrollment	9089	100%

For more information and links to all of our publications, visit our website leocohort.org

How will the LEO study benefit me?

The information you provide will help us gain a better understanding of Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, & Chronic Lymphocytic Leukemia. Your information will assist in improving patient care and quality of life to those with these diseases.



Have additional questions?
Reach out to us at leocohort@mayo.edu

Why should I continue to fill out the questionnaires even after I've achieved remission?

It is extremely important to our study! We try to follow patients over their lifetime and no evidence of disease is just as valuable information as those that have reported relapses or new treatments.

What does participation mean?

- ✓ Provide written consent
- ✓ Provide a blood sample at enrollment
- ✓ Complete questionnaires at enrollment and periodically following